Humans ; Myelodysplastic Syndromes ; diagnosis ; Prognosis

Humans ; Myelodysplastic Syndromes ; diagnosis ; therapy

Humans ; Myelodysplastic Syndromes ; diagnosis ; therapy

A total of 30 myelodysplastic syndromes (MDS) patients was analyzed to determine the clinical aspects and erythroid morphology in peripheral blood and bone marrow. The results are summarized as follows: 63.3% of patients was (50 years old. Male/Female ratio: 0.8. 46.7% were with lonely anemia and the rest were anemia combined with hemorrhages, infections, hepatosplenomegaly and lymphadenopathy. In peripheral blood: 63.4% of patients was with Hb<60g/l. 50% had normocrom - normocytic erythrocyte 96.7% of patients had dysmorphologic erythrocyte. In bone marrow: 46.6% were with hyperplasia of erythroid lineage, 33.6% were with hypoplasia of erythroid lineage, the rest (20%) were with normoplasia of erythroid lineage, 63.4% had dysmorphologic erythroblast, in which 36.7% was with ringed syderoblast
Myelodysplastic Syndromes ; blood ; diagnosis ; cytology ; Erythrocytes ; anemia

Animals ; Humans ; Myelodysplastic Syndromes ; diagnosis ; genetics ; therapy

Child ; Humans ; Myelodysplastic Syndromes ; diagnosis ; Prognosis

Humans ; Myelodysplastic Syndromes ; classification ; diagnosis ; Reference Standards

China ; Humans ; Myelodysplastic Syndromes ; diagnosis ; therapy

Anemia, Aplastic ; diagnosis ; Diagnosis, Differential ; Humans ; Myelodysplastic Syndromes ; diagnosis

The myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis associated with multilineage cytopenias leading to serious morbidity or mortality, and the additional risk of leukemic transformation. The management of patients with MDS can be very complex and varies according to both the clinical manifestations in individual patients as well as the presence of complicating medical conditions. However, therapeutic dilemmas still exist for MDS due to the multifactorial pathogenetic features of the disease, its heterogeneous stages, and the elderly patient population. For these reasons, proper guidelines for management are necessary. This review describes the proper diagnosis for MDS, decision-making approaches for optimal therapeutic options that are based on a consideration of patient clinical factors and risk-based prognostic categories, and the use of recently available biospecific drugs such as hypomethylating agents that are potentially capable of abrogating the abnormalities associated with MDS. Proper indications and methods for transplantation, response criteria, management for iron overload for highly transfused patients and specific considerations for MDS in childhood are also described. All of these topics were discussed at the third symposium of AML/MDS working party on 3 March, 2007.
Aged ; Diagnosis ; Hematopoiesis ; Humans ; Iron Overload ; Mortality ; Myelodysplastic Syndromes* ; Transplantation